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Background: The positive effects of early developmental intervention (EDI) on early child development have been
reported in numerous controlled trials in a variety of countries. An important aspect to determining the efficacy of
EDI is the degree to which dosage is linked to outcomes. However, few studies of EDI have conducted such analyses.
This observational cohort study examined the association between treatment dose and children’s development when
EDI was implemented in three low and low-middle income countries as well as demographic and child health factors
associated with treatment dose.
Methods: Infants (78 males, 67 females) born in rural communities in India, Pakistan, and Zambia received a
parent-implemented EDI delivered through biweekly home visits by trainers during the first 36 months of life.
Outcome was measured at age 36 months with the Mental (MDI) and Psychomotor (PDI) Development Indices of the
Bayley Scales of Infant Development-II. Treatment dose was measured by number of home visits completed and
parent-reported implementation of assigned developmental stimulation activities between visits. Sociodemographic,
prenatal, perinatal, and child health variables were measures as correlates.
Results: Average home visits dose exceeded 91% and mothers engaged the children in activities on average
62.5% of days. Higher home visits dose was significantly associated with higher MDI (mean for dose quintiles 1–2
combined = 97.8, quintiles 3–5 combined = 103.4, p = 0.0017). Higher treatment dose was also generally associated
with greater mean PDI, but the relationships were non-linear. Location, sociodemographic, and child health variables
were associated with treatment dose.
Conclusions: Receiving a higher dose of EDI during the first 36 months of life is generally associated with better
developmental outcomes. The higher benefit appears when receiving ≥91% of biweekly home visits and program
activities on ≥67% of days over 3 years. It is important to ensure that EDI is implemented with a sufficiently high dose
to achieve desired effect. To this end groups at risk for receiving lower dose can be identified and may require special
attention to ensure adequate effect.
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Programs of early developmental intervention (EDI)
implemented in the first years of life in children born
with, or at risk for, neurodevelopmental disability have
been shown to improve cognitive developmental out-
comes and consequently, their quality of life. EDI
includes various activities designed to enhance a young
child’s development, directly via structured experiences
and/or indirectly through influencing the care giving
environment [1]. The positive effects of EDI on early
child development have been reported in numerous
controlled trials in high-income countries [2,3], which
have been confirmed through meta-analyses [4,5] and
expert reviews [6-8]. Several trials of EDI with risk
groups of infants and young children have also been
conducted in low or low-middle income countries
(L/LMIC), which have also documented positive effects
on child development, by itself or in combination with
nutritional supplementation [9-16].
The involvement of parents in EDI is critical for
achieving positive outcomes [1,17-19], which can be
optimized by implementing EDI through home visits by
a parent trainer. This modality also matches well the
circumstances of many L/LMIC where families often live
far away from or have other barriers to reach providers
that could implement EDI [20]. An important aspect to
determining the efficacy of EDI is the degree to which
dosage impacts outcomes, and what constitutes “sufficient
dosage” [21]. Sufficient dosage with regard to EDI refers
to a participant receiving adequate exposure to the
intervention for it to be efficacious. Program intensity,
or dosage, typically is measured by the quantity and
quality the intervention actually achieved when imple-
mented [21,22], although it ideally should be deter-
mined based on the needs of the population at hand
[23]. Common indicators of dosage for EDI include
amount of time spent in a child development center,
number of home visits completed by a specialist training a
parent and/or engaging the child, or some indication of
parent engagement in the EDI.
Whereas there is more information linking outcomes
with treatment dose for pre-school programs [21,22],
despite its importance few studies of EDI implemented
in the first three years of life have conducted such
analyses. A few previous studies generally indicate that
children who receive more exposure to EDI display
greater improvements in their cognitive development
compared to those who receive less, even when differ-
ences in exposure were modest. Specifically, children
who received EDI (home and center based) for more
than 400 days, through age 3, exhibited significant
improvements in cognitive development, while smaller
but similar effects were evident among children who
received treatment between 350 and 400 days [24].Another study reported that optimal cognitive develop-
ment of children in EDI was not associated with their
background characteristics, such as birth weight or mater-
nal education, but with three aspects related to treatment
dosage: number of home visits received, days attending
child care, and number of parent meetings attended [18].
However these studies as well as the broader discus-
sions of implementation quality have focused on pro-
grams conducted in the United States [21,22]. The
applicability of this information to L/LMIC contexts is
unclear at present. The only EDI treatment dose study
conducted in a L/LMIC that we are aware of showed
that, as the frequency of home visits increased from
none, through monthly, biweekly, and weekly, develop-
mental gains at 30 months of age increased as well [25].
Given the potential for EDI to significantly impact the
development of children, and therefore the economic
development of nations in the long-term [26], it will be
important more broadly to examine treatment dose in
L/LMIC to inform the implementation of such efforts
on a larger scale.
Parents may vary in their level of participation in
home visit EDI programs due to a variety of factors.
Previous research has indicated higher treatment dose
among families participating in EDI who have better
financial and social resources [20,27-30]. Perinatal, neo-
natal, and other child health characteristics might also
predict treatment dose for an intervention intending to
promote the child’s development. Yet, studies that have
examined both social and health predictors of EDI treat-
ment dose are rare and have not considered a broad range
of possible predictors [15]. It is important to examine
various such factors in L/LMIC because they can iden-
tify processes that may influence parents’ adherence
with EDI and those who may need additional support.
In light of these gaps in our understanding, the aim
of the current study was to determine (1) whether there
is a dose effect in a home visiting EDI implemented
in three L/LMIC and (2) what sociodemographic and
health factors are associated with variation in treatment
dose. We examined two indicators of dose of EDI. As
in previous studies, the number of home visits com-
pleted over the course of the EDI was measured.
Another important treatment element is the extent to
which parents implement the assigned developmental
activities with the child during the time between home
visits, which we refer to as the program implementa-
tion dose. Despite its logical importance to the success
of home visiting EDI, we are not aware that parent pro-
gram implementation dose has been examined in EDI.
We hypothesize that increased dose as measured by
either indicator will be associated with better develop-
mental outcomes from EDI when implemented in three
L/LMIC.
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Data used to examine the association between treatment
adherence and developmental outcomes are from one
of the conditions of the Brain Research to Ameliorate
Impaired Neurodevelopment - Home-based Intervention
Trial (BRAIN-HIT), a randomized controlled trial (RCT)
detailed elsewhere (clinicaltrials.gov ID# NCT00639184)
[31,32]. Implemented in rural communities of India,
Pakistan, and Zambia, the overall aim of BRAIN-HIT
was to evaluate the efficacy of an EDI program on the
development of children in L/LMIC who are at-risk for
neurodevelopmental disability due to birth asphyxia that
required resuscitation. A group of children who did not
require resuscitation at birth was evaluated using the
same protocol to compare the efficacy of the EDI in
those with and without birth asphyxia.
As detailed elsewhere [32,33], mental development at
36 months of age was better in children with birth
asphyxia who had received the EDI compared with those
in the control condition (effect size = 4.6 points on the
standardized scale from the Bayley Scales of Infant
Development, see below), but there was no difference
between trial conditions in the children without birth
asphyxia. Psychomotor development was likewise higher
in the EDI group, in this case for both the children with
(effect size = 5.4) and without (effect size = 6.1) birth
asphyxia, compared to those in the control condition.
The issue of the effect of treatment dose on develop-
ment is only relevant for the active EDI condition, and
not the comparison condition, which intended to control
for placebo, observation, and time effects and lacked a
theoretically based developmental intervention. There-
fore, only data from those randomized to receive EDI
were analyzed in the present research, making this an
observational study of that cohort. BRAIN-HIT was
approved by the Institutional Review Board at each site
and was conducted in accord with prevailing ethical
principles.
Study population
Infants with birth asphyxia (resuscitated) and infants
without birth asphyxia or other perinatal complications
(non-resuscitated), born from January 2007 through June
2008 in rural communities in three sites in India, Pakistan
and Zambia, were matched for country and chronological
time and randomly selected from those enrolled in the
First Breath Trial [34]. Infants were screened for enroll-
ment into the BRAIN-HIT during the 7-day follow-up
visit after birth [31], and were ineligible if: (1) birth weight
was less than 1500 grams, (2) neurological examination at
seven days of age (grade III by Ellis classification) [35],
was severely abnormal (because they were not expected to
benefit from EDI), (3) mother was less than 15 years old
or unable/unwilling to participate, or (4) mother was notplanning to stay in the study area for the next three
years. Birth asphyxia was defined as the inability to
initiate or sustain spontaneous breathing at birth using
WHO definition (biochemical evidence of birth asphyxia
could not be obtained in these settings) [36]. A list of
potential enrollees was distributed to the investigators
in each country to obtain written consent for the study,
which was obtained during the second week after birth
and before randomization to intervention conditions of
the BRAIN-HIT.
Intervention procedures
Investigators at each research site selected EDI parent
trainers who were trained in an initial 5-day workshop,
which was led by the same experts at each research site.
A second workshop was conducted before participating
children began to reach 18 months of age to adapt the
approach to children up to 36 months, again conducted
by the same experts at each site. To maintain quality of
implementation, the trainers were supervised with obser-
vations during actual home visits and constructive feed-
back was provided on a regular basis.
Each parent–child pair was assigned to the same trainer
throughout the trial whenever possible, who was scheduled
to make a home visit every two weeks over the 36-month
trial period. As elaborated elsewhere [31,32], the trainer
presented one or two playful learning activities during
each visit targeting developmentally appropriate mile-
stones. These activities cover a spectrum of abilities
across the cognitive, social and self-help, gross and fine
motor, and language domains. The parent practiced the
activity in the presence of the trainer who provided
feedback. Cards depicting the activities were then left with
the parent, who was encouraged to apply the activities in
daily life with the child until the next home visit. The
trainer introduced new activities in subsequent visits to
enhance the child’s developmental competencies.
Treatment dose indicators
Two indicators of treatment dose were calculated. Home
visit dose was measured based on each parent trainer
keeping a record of visit dates. Following the first visit,
visits were scheduled to occur every two weeks until the
completion of the trial. A home visit was completed on
schedule if it occurred within its assigned two week
window following the preceding visit. We calculated the
percentage of scheduled home visits completed for each
participant for the full 36-month trial. The reason for
each missed visit was coded as due to illness, weather,
death in family, refusal, child or mother unavailable for
another reason, parent trainer schedule conflict, and
other reasons.
Program implementation dose was measured based on
maternal report obtained by the trainer at each home
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been implemented since the previous visit. First, the
number of days between subsequent completed visits
was calculated (Yn). If the time between two home visits
extended beyond 30 days, a maximum of 30 days was
used. Program implementation credits were assigned for
the time period between visits based on the mother’s
report of implementation of activities, as follows: “not at
all” (creditn = 1), “about one-quarter of days or less”
(creditn = Yn*.25), “about one-half of days” (creditn =
Yn*.50), “about three-quarters of days” (creditn = Yn*.75),
and “almost every day or more” (creditn = Yn). The
credits were then added together over the trial period,
divided by the number of possible credits, and multi-
plied by 100. Thus, this score estimates the percent of
days between each home visit that the mother reported
implementing child stimulation activities. As an add-
itional descriptive measure of treatment dose, the par-
ent trainer was surveyed at the conclusion of the study
to estimate how often the activities had been imple-
mented between the home visits, using a five-point scale
(from “never” to “always”).Developmental outcome measures
The Bayley Scales of Infant Development – II (BSID) [37]
was selected as the main outcome measure for this trial
because it has been used extensively in various L/LMIC.
The BSID underwent pilot-testing at each site to verify
validity in the local context and a few items were
slightly modified to make it more culturally appropriate
(e.g., image of a sandal instead of a shoe). Evaluators
across the sites were trained to standards in joint 4-day
workshops conducted by experts before each yearly
evaluation. The BSID was administered directly to each
child by certified study evaluators, who were masked to
the children’s birth history and randomization, in the
appropriate language with standard material. Both the
Mental Developmental Index (MDI) and Psychomotor
Developmental Index (PDI) were used to measure
developmental outcomes. Scores from the 36-month
assessment, obtained just after the completion of the
EDI, were used in this analysis as an indicator of treat-
ment outcome.Health and sociodemographic measures
Perinatal and neonatal health variables were obtained from
records kept by the FIRST BREATH Trial [34]: child gen-
der, birth weight (1500 g-2499 g, 2500 g-2999 g, 3000 + g),
gestational age (28–36 weeks, 37+ weeks), number of pre-
natal visits (0, 1–3, 4+), and parity. Additional child health
variables obtained as part of this trial at 12 months of
age included weight for age/sex (<5th, 5th-14th, 15th +
percentile) and complete immunization status.Family demographic variables were obtained at enroll-
ment in BRAIN-HIT using a structured parent interview:
maternal age, education (none and illiterate, none but
literate or primary, literate with some secondary), family
assets and home living standard. The presence of 11
family assets (e.g., radio, refrigerator, bicycle) were tallied
as a Family Resources Index and classified into three levels
(0–1, 2–4, 5+). A Home Living Standard Index was
calculated based on seven indicators (e.g., home building
material, water source, type of toilet) and classified into
three levels (0–4, 5–7, 8+). A socio-economic status (SES)
measure was used to classify participants into three groups
(quintile 1–3, 4, 5) [38].
Statistical analysis
Descriptive statistics were computed for child health and
family demographic characteristics, treatment dose indi-
cators (home visits dose and protocol implementation
dose), and developmental outcomes (MDI and PDI at
36-months) for all individuals randomized to receive
EDI. Child health and demographic characteristics were
summarized separately for those randomized to receive
EDI and included in the treatment dose analysis and
those who were excluded from this analysis, and differ-
ences in mean values for continuous variables were
tested using t-tests and categorical measures were tested
using chi-square and Fisher exact tests. A Pearson cor-
relation statistic was computed between the treatment
dose characteristics.
Aim 1
In the absence of established criteria for adequate treat-
ment dose for EDI and to determine where the effective-
ness of the intervention may plateau, both treatment
dose indicators were divided into quintiles. Those in
quintile 1 had lowest dose and those in quintile 5 had
the highest dose of the indicator in question. Descriptive
statistics for the 36-month MDI and PDI were calculated
for each quintile. General linear models were used to
evaluate the associations of treatment dose quintile
with 36-month MDI and PDI. In addition to the treat-
ment dose indicator in question, covariates of interest
included resuscitation status at birth, 12-month MDI
or PDI, and site. If the omnibus 4-degree of freedom
test for either MDI or PDI provided evidence of signifi-
cant differences across quintiles of treatment dose,
step-down tests were used to evaluate where those
differences occurred.
Aim 2
To evaluate associations with treatment dose, initially all
sociodemographic and child health variables and trial
location were entered into linear regression models
separately to predict both treatment dose variables.
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ables that demonstrated P ≤ 0.20 in univariate associ-
ation with the adherence variable in question when
either adjusted by location alone or location and the
variable by location interaction. We employed back-
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Table 1 Child health and family demographic characteristics of study sample
Characteristica Inclusion in analysis - n (%) Total p-valueb
Yes No
Enrolled - N 145 59 204 –
Male gender- n/N (%) 78/141 (55.3) 34/59 (57.6) 112/200 (56.0) 0.7643
Birth weight (grams) - N 139 59 198 0.1109
1500 - 2499 30 (21.6) 13 (22.0) 43 (21.7)
2500 - 2999 51 (36.7) 30 (50.8) 81 (40.9)
≥ 3000 58 (41.7) 16 (27.1) 74 (37.4)
Gestational age-mean (std) 37.9 (2.0) 37.8 (1.9) 37.9 (2.0) 0.7804
Preterm (<37 mos.) - n/N (%) 40/142 (28.2) 16/59 (27.1) 56/201 (27.9) 0.8798
Resuscitated - n/N (%) 59/145 (40.7) 19/59 (32.2) 78/204 (38.2) 0.2581
Prenatal care visits-N 145 59 204 0.0151
0 35 (24.1) 4 (6.8) 39 (19.1)
1-3 48 (33.1) 22 (37.3) 70 (34.3)
4 or more 62 (42.8) 33 (55.9) 95 (46.6)
Weight for age and sex at 12 mos-N 137 43 180 0.0407
<5th % tile for age in months 40 (29.2) 20 (46.5) 60 (33.3)
5th-14th % tile for age in months 16 (11.7) 7 (16.3) 23 (12.8)
> = 15th % tile for age in months 81 (59.1) 16 (37.2) 97 (53.9)
Immunization complete 12 mos-n/N (%) 106/142 (74.6) 41/43 (95.3) 147/185 (79.5) 0.0032
Maternal Age (Years)- Mean (Std) 25.5 (5.7) 24.3 (4.0) 25.1 (5.3) 0.0844
Maternal schooling completed-N 136 58 194 0.5144
None and illiterate 68 (50.0) 25 (43.1) 93 (47.9)
Literate or primary schooling 36 (26.5) 20 (34.5) 56 (28.9)
Literate and some secondary schooling 32 (23.5) 13 (22.4) 45 (23.2)
Parity (including child enrolled in study) - Mean (Sd) 3.1 (2.2) 2.4 (1.3) 2.9 (2.0) 0.0110
Family Resources Index (# items present in home) - N 145 59 204 <.0001
0-1 55 (37.9) 11 (18.6) 66 (32.4)
2-4 49 (33.8) 40 (67.8) 89 (43.6)
5+ 41 (28.3) 8 (13.6) 49 (24.0)
aMeasured at enrollment unless otherwise indicated.
bDifferences in mean values for continuous variables were tested using t-tests and categorical measures were tested using chi-square and Fisher exact tests;
bold indicates significant p < .05.
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withdrawal (n = 6), loss to follow up (n = 5), incomplete
36-month BSID-II (n = 39) due to administration errors,
home-visit data unavailable (n = 1), or another reason
(n = 1). Three children were included in the analysis
who completed the 36-month evaluation but discontin-
ued the EDI prior to the end of the study (two because
the family had insufficient time to fulfill study require-
ments and one because the family moved). When com-
pared to those who were included in the analysis
(Table 1), children excluded (n = 59) were significantly
(p < .05) more likely to have been less than the 5th per-
centile in weight and completed all immunizations at
12-months of age, and their mothers to have had pre-
natal care, lower parity, and more family resources.Description of developmental outcomes and treatment
dose
The sample had an unadjusted mean (SD) MDI = 101.2
(10.4) and PDI = 106.8 (14.1) at 36-months. Average
home visits dose was 91.4% over 36 months, when 8,990
visits out of 9,841 were completed on schedule every
two weeks, and 95% of the participants achieved 80% or
greater home visits dose. The most common reason for
a missed visit was the inability to locate the mother and
child at home at the scheduled time (40.3%), for example
because the family was travelling away from the home
or had moved temporarily. However, the second most
common reason was those related to the parent trainer,
such as being ill or having a conflict with another meeting
(23.9%). Child or mother unavailable for other reasons
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baby was sleeping, and weather (10.0%) were the only
other reasons accounting for at least 10% of the missed
visits. Mother or family directly refusing the home visit at
the scheduled time was rare (2.5%).
Mothers reported engaging the child in the assigned
activities on an average of 62.5% of days throughout the
36 month period. This protocol implementation dose
equates to practicing the intervention activities 4.4 days
per week or 674 days over the 36 month trial period.
Home visits dose was modestly correlated with protocol
implementation dose (r = 0.35). Parent trainers esti-
mated at the end of the trial that 66.2% of families prac-
ticed the intervention “always” or “almost always”
throughout the 36 months.
Associations between treatment dose and developmental
outcomes
Higher home visits dose was associated with higher MDI
at 36-months (Figure 2). Specifically, quintiles 1–2 mean
MDI = 98, while quintiles 3–5 mean MDI = 103 (Table 2).
General linear models of MDI supported this relation-
ship when home visits dose was entered as a primary MDI by home visits dose quintiles






























































Figure 2 Mental (MDI) and Psychomotor (PDI) Development Index bypredictor and site, resuscitation status at birth, and 12-
month MDI were entered as covariates (Table 2). Most
notably, in the model with only home visits dose (Model
1) and the model which included site (Model 2), mean
MDI for quintiles 1 and 2 was significantly lower than
quintiles 3–5. A step-down test comparing mean MDI
for those with home visit dose below the 40th percentile
(quintiles 1 and 2) to those with home visit dose above
the 40th percentile (quintiles 3–5), provided estimates of
97.8 and 103.4 (p = 0.0017), respectively . Adjusting by
site increased the magnitude of the difference by at least
25% (96.8 vs. 103.9, p = 0.0005). When adjusting for 12-
month MDI and the interaction between dose and 12-
month MDI (Model 5), the adjusted mean scores for the
dose quintiles mirrored unadjusted scores, with quintiles
1–2 consistently lower than quintiles 3–5 (p <0.0001).
The lower limit for quintile 3 includes those receiving a
minimum of 91% of all the planned home visits.
Based on the same general linear model analysis
(Table 2), home visit dose was not significantly associ-
ated with PDI at 36 months when considered by itself
(Model 1) or when adjusted by site, resuscitation status,
and 12-month PDI (Models 2–4). However, there was a PDI by home visits dose quintiles
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Table 2 Treatment dose modeling results and mean mental (MDI) and psychomotor (PDI) developmental index by
quintiles
Outcome Dose indicator Model
number
Covariates p-values Least squares means for quintiles
Dosea Covariate Q1 Q2 Q3 Q4 Q5
MDI Home Visits Dose 1 – 0.0443 97.8 97.9 103.5 103.5 103.1
2 Site 0.0150 0.2159 96.3 97.0 103.3 104.4 104.2
3 Resuscitation 0.0802 0.5155 98.1 98.1 103.5 103.4 103.2
4 12 Mo MDI 0.0296 <0.0001 98.3 97.6 102.8 103.8 103.4
5 12 Mo MDI <0.0001 <0.0001 98.6 97.4 103.4 103.6 103.1
Interaction <0.0001
PDI Home Visits Dose 1 – 0.0669 102.9 102.6 108.5 111.4 108.7
2 Site 0.0823 0.1692 102.9 102.2 109.0 112.2 108.7
3 Resuscitation 0.1160 0.5346 103.3 102.9 108.5 111.3 108.7
4 12 Mo PDI 0.2588 0.0024 104.2 103.0 108.4 110.2 108.1
5 12 Mo PDI 0.0030 0.0421 106.5 103.3 108.5 111.0 109.4
Interaction 0.0135
MDI Program Implemen-tation Dose 1 – 0.1901 100.0 98.0 101.2 104.4 102.2
2 Site 0.2016 0.8523 100.0 98.0 101.8 104.5 102.0
3 Resuscitation 0.2225 0.2338 100.1 98.4 101.5 104.6 102.4
4 12 Mo MDI 0.2661 <0.0001 100.3 98.4 100.9 103.5 103.0
5 12 Mo MDI 0.0434 0.0005 100.1 98.3 100.9 105.0 103.1
Interaction 0.0641
PDI Program Implemen-tation Dose 1 – 0.5182 107.4 105.4 103.6 109.6 108.1
2 Site 0.8002 0.3009 107.1 105.8 105.1 109.5 108.0
3 Resuscitation 0.5907 0.2590 107.5 105.9 104.0 109.7 108.2
4 12 Mo PDI 0.7654 0.0007 108.2 105.3 104.7 108.7 107.3
5 12 Mo PDI 0.3491 0.0011 108.6 105.3 105.5 109.6 107.2
Interaction 0.4095
aBold indicate significant p < .05 for the relationship between the treatment dose indicator and the developmental outcome.
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month PDI when adjusting for the 12-month PDI and
its interaction with dose (Model 5). Here again, a home
visit dose above the 40th percentile (quintiles 3–5) re-
sulted in higher estimated PDI (108.5 – 111.0) compared
with below this percentile (103.3 – 106.5)
Higher program implementation dose was associated
with slightly higher MDI at 36-months compared to
those with a lesser dose. Quintiles 1–2 had a mean MDI
of 100 or lower, while quintiles 4–5 has a mean MDI of
102 or higher (Table 2), and the difference appears larger
when considering the medians of these quintiles. In a
general linear model of 36-month MDI (Table 2), program
implementation dose was not a significant predictor by it-
self (Model 1). However, prediction of program imple-
mentation dose when adjusting for 12-month MDI and its
interaction with dose (Model 5) indicated that greater
dose was associated with higher MDI (adjusted mean
Q1 = 100.1 vs. Q5 = 103.1, p = 0.0434). PDI at 36 months
was not linearly associated with program implementationdose (Table 2). Rather, mean PDI across quintiles followed
a U-shape with the highest mean scores for quintiles 1, 4
and 5. The lower limit for quintile 4 includes those imple-
menting activities on 67% of days on average over the trial
period.
Factors associated with treatment dose
The following variables were associated with home visits
dose at P ≤ 0.20 when either adjusted by location or by
the location by variable interaction: maternal education,
parity, family resources, prenatal visits, birth attendant,
1 minute Apgar, preterm birth, and child’s weight at 36-
months. These variables were entered into a generalized
linear model along with those interaction terms with lo-
cation that were significant. After backward elimination,
the final model (R2 = .19) included parity (82.9 ± 3.0 [ad-
justed mean ± standard error] with 1 child, 79.7 ± 2.8
with 2–3 children, and 90.8 ± 3.5 with 4+ children [p =
0.0382]), 1 minute Apgar (86.9 ± 2.6 for <9 and 82.0 ±
2.6 for 9+ [p = 0.1754]), location (adjusted mean ranged
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preterm by location interaction(p = 0.0020). There was a
substantial difference in relationship to home visits dose
by prematurity across location. Location A had higher
dose for term children (65.8 ± 6.3 for preterm and 85.3 ±
4.0 for term). Location B had essentially the same dose be-
tween groups (92.8 ± 5.9 for preterm and 95.4 ± 2.9 for
term). Location C had considerably higher dose in pre-
term children (90.5 ± 4.6 for preterm and 76.9 ± 3.5 for
term).
The following variables were associated with program
implementation dose at P ≤ 0.20 when either adjusted by
location or by the location by variable interaction: home
visit adherence rate, maternal education, parity, family
resources, living standard index, prenatal care, 1 minute
Apgar, preterm birth, and weight at birth, 12, 24, and
36 months. These variables were entered into a model
along with those interaction terms with location that
were significant. After backward elimination and adjust-
ing for location, the final model (R2 = .25) included home
visit adherence rate (a one percent increase in home visit
adherence resulted in a 0.64 ± 0.18 percent increase in
program implementation adherence, p = 0.0004), maternal
education (70.0 ± 2.8 for secondary/university and 60.9 ±
2.4 for none/illiterate [p = 0.0400]), prenatal care (71.0 ±
2.9 for 5+ visits and 65.3 ± 3.5 for no care [p = 0.0170]),
weight at 12 months (66.7 ± 1.7 for >85th percentile and
61.1 ± 2.2 for <5th percentile [p = 0.0917]), and location
(adjusted mean ranged from 59.5 - 69.1, [p = 0.0019]).
None of the interaction terms were retained in the final
model.
Discussion
Consistent with our hypothesis, receiving a higher dose
of EDI during the first 36 months of life, as indicated by
number of home visits by a parent trainer and reported
implementation of program activities between these
home visits, is generally associated with better develop-
mental outcomes at 36 months of age. This benefit is
confirmed more consistently for mental compared to
psychomotor development, and appears to some extent
to be moderated by developmental status at 12 months.
The higher benefit from treatment appears for those re-
ceiving at least 91% of the biweekly home visits and pro-
gram activities on at least 67% of days on the average or
716 days over 36 months. In the context of a general de-
velopmental benefit demonstrated to be due to this pro-
gram of EDI [32,33], the difference in benefit from those
receiving smaller vs. larger treatment doses is modest,
about three to six points on a standardized developmen-
tal measure (M = 100, SD = 15). Variation in treatment
dose was associated with child health and family socio-
demographic factors as well as by trial location. In par-
ticular, more frequent use of the stimulation activitieswas reported by better educated mothers who had
already engaged in a schedule of prenatal care and had
infants who reached a higher weight in the first year.
Limitations with this research include that results may
not be generalizable to other L/LMIC or to other types
of EDI programs. Moreover, we do not have independent
observations of the implementation of the program ac-
tivities at home, either in terms of quantity or quality.
Program implementation dose was measured exclusively
by self-report, which might have been susceptible, for
example, to recall and acquiescence biases. Direct obser-
vation, though challenging to use in this context, should
be less biased. Even though this trial of EDI enrolled one
of the largest samples reported in L/LMIC, the sample
size is still modest. This EDI was not intended for se-
verely impaired infants. There was a 29% loss at follow-
up, which included a higher proportion of parents with
better resources. Power to detect significant associations
with treatment dose was quite limited despite that this
trial of EDI enrolled one of the largest samples reported
in L/LMIC. Although a broad range of health factors
were examined for associations with treatment dose, it
would be useful to learn from mothers what other fac-
tors possibly influenced their use of the stimulation ac-
tivities, such as motivation, belief in their efficacy, and
family support. Treatment dose had a limited effect on
psychomotor development, which may reflect that the
EDI was not as successful in addressing development in
these domains or be due to children reaching ceiling ef-
fects of the BSID at 36 months of age.
Only a few studies had previously examined whether
dose of EDI during the first three years of life is associ-
ated with developmental outcomes. Our findings are
consistent with prior studies that have generally reported
that children who receive more exposure to EDI, how-
ever measured, display greater improvements in their
cognitive development [18,21,24,25]. Although only one
of these studies was conducted in a L/LMIC, this too re-
ported modest differences on developmental outcomes
associated with varying home visit dose [19]. Program im-
plementation dose was not examined. Given the differ-
ences between the EDI programs for which treatment
dose has been evaluated, countries where implemented,
populations targeted, and how treatment dose has been
operationalized, it is difficult to generalize from this small
body of research. It is impossible yet to establish a mini-
mum effective dose. Given the importance of determining
the efficacy of EDI in L/LMIC, which depends in part on
information about sufficient dose, further research on the
relationship between dose and outcome is much needed.
Evaluations of EDI need to include such analysis to inform
setting minimal targets for effective implementation.
EDI provided via home visiting has quite consistently
shown to promote development in children in L/LMIC
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showing that the same program can do so across quite
different cultures, represented here by India, Pakistan,
and Zambia [32]. Whereas the identical program was
used, for example in terms of the same basic structure
and developmental activities, the social process transpir-
ing in the home visits would naturally vary as a function
of the specific people engaged and their local culture.
One strength of home visiting EDI is that in this manner
it can be both programmatically structured yet culturally
flexible.
Conclusions
The body of research in which the current study is em-
bedded quite consistently establishes that within an ef-
fective EDI, a higher dose is generally associated with
better developmental outcomes. A large body of research
indicates that EDI can improve early development of
children in L/LMIC. Therefore EDI should be one ap-
proach used in L/LMIC to lay the foundation for im-
proving longer-term outcomes of its population and
interrupting intergenerational transmission of poverty
[26]. Yet, for this to be successful, efforts to implement
EDI for children need to ensure that program elements
reach the children at the intended intensity. Groups of
children at risk for receiving lower treatment dose may
require special attention to ensure adequate effect.
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